Symposia: CAR-T Cell Therapies: Basic and Translational
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Combination therapy, Lymphoid Leukemias, Research, Acute Myeloid Malignancies, AML, Adult, ALL, Fundamental Science, Clinical trials, Translational Research, Lymphomas, Non-Hodgkin lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Chemotherapy, Genomics, Bioinformatics, Clinical Research, Pediatric, Diseases, Immune mechanism, Treatment Considerations, Biological therapies, Immunology, Immunotherapy, Aggressive lymphoma, Lymphoid Malignancies, Non-Biological therapies, Computational biology, Young adult , Myeloid Malignancies, Biological Processes, Molecular biology, Technology and Procedures, Gene editing, Profiling, Study Population, Human, Pathogenesis, Animal model, Omics technologies, Pathology
Type: Oral
Hematology Disease Topics & Pathways:
Combination therapy, Lymphoid Leukemias, Research, Acute Myeloid Malignancies, AML, Adult, ALL, Fundamental Science, Clinical trials, Translational Research, Lymphomas, Non-Hodgkin lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Chemotherapy, Genomics, Bioinformatics, Clinical Research, Pediatric, Diseases, Immune mechanism, Treatment Considerations, Biological therapies, Immunology, Immunotherapy, Aggressive lymphoma, Lymphoid Malignancies, Non-Biological therapies, Computational biology, Young adult , Myeloid Malignancies, Biological Processes, Molecular biology, Technology and Procedures, Gene editing, Profiling, Study Population, Human, Pathogenesis, Animal model, Omics technologies, Pathology
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Grand Hall C
(Manchester Grand Hyatt San Diego)
Moderators:
Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center
and
Saar Gill, MD, PhD, University of Pennsylvania
Disclosures:
Haubner: Takeda Pharmaceuticals: Patents & Royalties. Gill: Mission Bio: Membership on an entity's Board of Directors or advisory committees; Asher Biotherapeutics: Research Funding; Novartis: Patents & Royalties, Research Funding; Carisma: Current holder of stock options in a privately-held company; Interius: Current holder of stock options in a privately-held company, Research Funding.
This session will focus on CAR T cells for AML and therapies that target myeloid cells to improve CAR T cell outcomes. So, the theme of the session will be the myeloid axis. The selected abstracts will range from correlative science to novel targets in preclinical models.
4:00 PM
4:15 PM
4:30 PM
4:45 PM
5:00 PM
5:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH